Search Results 511-520 of 17115 for monoclonal antibody

1. A Study to Evaluate Regorafenib with Cetuximab or Panitumumab to Treat Unresectable, Locally Advanced, or Metastatic Colorectal Cancer - Mayo Clinic

   Regorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab or panitumumab, ...

2. Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   ... monoclonal antibody: Refractory MM is defined as the development of disease progression during therapy with an anti-myeloma regimen or within 60 days of the ...

3. Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery - Mayo Clinic

   Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find ...

4. Experimental Treatments Clinical Trials - Mayo Clinic Research

   ... monoclonal anti-CD20 antibody, for patients with relapsed or refractory B Cell non-Hodgkin lymphoma (NHL). . Mayo Clinic Footer. Request Appointment · Give ...

5. FT516 in Subjects With Advanced Hematologic Malignancies - Mayo Clinic

   ... monoclonal antibodies, in B-cell lymphoma. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into ...

6. Non-Small Cell Lung Cancer Clinical Trials - Mayo Clinic Research

   Ramucirumab is a monoclonal antibody that may prevent the growth of new ... Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.

7. Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery - Mayo Clinic

   Irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab and bevacizumab, ...

8. A Study to Determine the Effectiveness of Early Intensive vs. Escalation Approach to Treat Relapsing/Remitting Multiple Sclerosis - Mayo Clinic

   About this study. The purpose of this study is to determine whether an EHT approach to DMT, defined as use of one of five monoclonal antibodies (alemtuzumab ...

9. Doxorubicin Hydrochloride, Cyclophosphamide, And Paclitaxel With Or Without Bevacizumab In Treating Patients With Lymph Node-Positive Or High-Risk, Lymph Node-Negative Breast Cancer - Mayo Clinic

   Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of breast ...

10. First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects with Acute Myelogenous Leukemia and Selected B-cell Cancers - Mayo Clinic

    Participation eligibility · Must be at least 4 weeks (for FL) or 2 weeks (for DLBCL) since prior cytotoxic, biologic, monoclonal antibody, or investigational ...